Exact Sciences Corp (EXAS)

18.09
0.33 1.79
NASDAQ : Health Care
Prev Close 18.42
Open 18.53
Day Low/High 17.94 / 18.83
52 Wk Low/High 4.67 / 25.07
Volume 2.40M
Avg Volume 2.78M
Exchange NASDAQ
Shares Outstanding 108.41M
Market Cap 2.01B
EPS -1.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Major Indices' Support Holds, But Momentum Eases

Major Indices' Support Holds, But Momentum Eases

Biotech shares have gained from takeovers in that sector.

Exact Sciences To Report $99 Million In Revenues, 150 Percent Growth For 2016

Exact Sciences To Report $99 Million In Revenues, 150 Percent Growth For 2016

- Preliminary revenues between $99.0 million and $99.5 million for 2016, a year-over-year increase of 150 percent;

Cologuard Earns Positive Review From Blue Cross Blue Shield Association

Cologuard Earns Positive Review From Blue Cross Blue Shield Association

Cologuard Covered for 70 Percent of Addressable Population

Cologuard Available To Humana Members As In-Network Colon Cancer Screening Option

Cologuard Available To Humana Members As In-Network Colon Cancer Screening Option

Members of Fifth Largest Commercial Insurer will have Access to Non-Invasive Colon Cancer Screening Test and Compliance Service

Exact Sciences Appoints Jeff Elliott Chief Financial Officer

Exact Sciences Appoints Jeff Elliott Chief Financial Officer

Respected diagnostics industry expert will help lead efforts to capitalize on market opportunity for Cologuard

Bullish and Bearish Reversals for the Week

Bullish and Bearish Reversals for the Week

Here's a window into what institutional investors may be doing and how to profit from that.

Cologuard® Covered For TRICARE Beneficiaries

Cologuard® Covered For TRICARE Beneficiaries

America's veterans, military personnel and their families provided access to non-invasive, at-home colon cancer screening option without copay

Exact Sciences (EXAS) Stock Climbs, Colorectal Cancer Screening Guidelines Updated

Exact Sciences (EXAS) Stock Climbs, Colorectal Cancer Screening Guidelines Updated

Exact Sciences (EXAS) stock is gaining on Monday after the National Committee for Quality Assurance updated its guidelines on colorectal cancer screening tests.

Exact Sciences Announces Inclusion Of Cologuard® In HEDIS Quality Measures

Exact Sciences Announces Inclusion Of Cologuard® In HEDIS Quality Measures

Cologuard offers opportunity for health plans, systems & providers to improve quality ratings

2 Bullish Stock Picks and 2 Stocks to Sell Short

2 Bullish Stock Picks and 2 Stocks to Sell Short

Here's a look at two stocks that are trending higher and two that are ripe for short-selling.

EXAS: Insiders vs. Shorts

EXAS: Insiders vs. Shorts

The most recent short interest data was recently released for the 08/31/2016 settlement date, and EXACT Sciences Corp. is one of the most shorted stocks of the Russell 3000, based on 8.37 "days to cover" versus the median component at 6.39.

4 Breakout Stocks to Watch

4 Breakout Stocks to Watch

These four stocks are looking strong technically, either breaking out or approaching breakout levels.

10 Best-Performing Stocks This Earnings Season

10 Best-Performing Stocks This Earnings Season

Which stocks have had the highest gains following earnings? Bespoke Investment came up with a list of the 40 stocks that had the best performance on their earnings reaction days.

Cologuard® Coverage Expands With Updated Policies From HCSC And Florida Blue

Cologuard® Coverage Expands With Updated Policies From HCSC And Florida Blue

Positive medical policies from health plans that collectively insure 18 million people

4 Tech and Biotech Stocks With Momentum to Watch

4 Tech and Biotech Stocks With Momentum to Watch

Here are four biotech and technology stocks showing strong technical momentum.

Exact Sciences (EXAS) Stock Falling After Public Offering

Exact Sciences (EXAS) Stock Falling After Public Offering

Exact Sciences (EXAS) announced today that it would be offering 8.5 million shares of common stock.

Exact Sciences Announces Agreement To Sell 7,000,000 Common Shares

Exact Sciences Announces Agreement To Sell 7,000,000 Common Shares

Exact Sciences Corporation (NASDAQ: EXAS) today announced an agreement to sell 7,000,000 shares of its common stock to Jefferies LLC, Robert W.

Strong On High Relative Volume: Exact (EXAS)

Strong On High Relative Volume: Exact (EXAS)

Trade-Ideas LLC identified Exact (EXAS) as a strong on high relative volume candidate